The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.

@article{Kasichayanula2013TheIO,
  title={The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.},
  author={Sreeneeranj Kasichayanula and Xiaoni Liu and Melanie Pe Benito and Ming Yao and Marc Pfister and Frank P Lacreta and W Griffith Humphreys and David W. Boulton},
  journal={British journal of clinical pharmacology},
  year={2013},
  volume={76 3},
  pages={432-44}
}
AIM(S) This study assessed the effect of differences in renal function on the pharmacokinetics and pharmacodynamics of dapagliflozin, a renal sodium glucose co-transporter-2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus (T2DM). METHODS A single 50 mg dose of dapagliflozin was used to assess pharmacokinetics and pharmacodynamics in five groups: healthy non-diabetic subjects; patients with T2DM and normal kidney function and patients with T2DM and mild, moderate or severe… CONTINUE READING